MARKET

LUCD

LUCD

Lucid Diagnostics Inc.
NASDAQ
0.9911
-0.0289
-2.83%
After Hours: 1.030 +0.039 +3.92% 19:57 05/15 EDT
OPEN
1.010
PREV CLOSE
1.020
HIGH
1.030
LOW
0.9501
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
1.700
52 WEEK LOW
0.9495
MARKET CAP
193.52M
P/E (TTM)
-2.1164
1D
5D
1M
3M
1Y
5Y
1D
Lucid Diagnostics Is Maintained at Buy by Maxim Group
Dow Jones · 18h ago
Lucid Diagnostics Price Target Cut to $2.00/Share From $3.00 by Maxim Group
Dow Jones · 18h ago
Maxim Group Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2
Benzinga · 18h ago
Lucid Diagnostics price target lowered to $2 from $3 at Maxim
TipRanks · 23h ago
PAVmed Q1 FY26 net loss widens to $7 million; operating expenses rise to $8.1 million
PUBT · 1d ago
Lucid Diagnostics Price Target Maintained With a $2.50/Share by BTIG
Dow Jones · 1d ago
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Benzinga · 1d ago
Analyst Reiterates Buy on Lucid, Maintains $2.50 Price Target Ahead of Potential Medicare Catalyst
TipRanks · 1d ago
More
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

Webull offers Lucid Diagnostics Inc stock information, including NASDAQ: LUCD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUCD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LUCD stock methods without spending real money on the virtual paper trading platform.